Vaccination Coverage for Medically Indicated Vaccines in a Convenience Sample of Severely Immunocompromised Patients with COVID-19: An Observational Cohort Study.

Publication date: Dec 09, 2024

In recent decades, the number of immunocompromised patients (ICPs) has increased significantly. ICPs have an impaired immune system, making them susceptible to complicated infections. To protect them from infections, ICPs are eligible to receive several medically indicated vaccines. To obtain insight into the uptake of these medically indicated vaccines, we determined the coverage of these vaccines in ICPs. This observational cohort study was conducted at the University Medical Centre Utrecht, the Netherlands, from September 2021 to April 2022. All adult ICPs admitted for COVID-19 were asked to complete a questionnaire on their vaccination history (pneumococcal, herpes zoster, human papillomavirus vaccination, influenza, and COVID-19 vaccines) and history of vaccine-preventable infections. In addition, patients’ vaccination history was reviewed in medical files. A total of 115 patients completed the questionnaire and were included. Although all patients had an indication for pneumococcal vaccination, only 22 received it (19%). Coverage for herpes zoster was low (1%, 1/106 eligible patients). Coverage for human papillomavirus vaccination (HPV) was also low (40%, two out of five eligible patients). In contrast, 92% of patients received vaccination against SARS-CoV-2, and 77% of patients received seasonal influenza vaccination. Although coverage for influenza and COVID-19 vaccination was high in ICPs, coverage for other medically indicated vaccines was low. Identifying which factors contributed to high COVID-19 and influenza vaccine uptake can help to improve vaccination rates for the other recommended vaccines. Clear guidelines for clinicians and the removal of organizational obstacles are needed to improve vaccination coverage.

Open Access PDF

Concepts Keywords
Clinicians immunization schedule
Decades immunocompromised patients
Papillomavirus medically indicated vaccines
September vaccination coverage
Vaccines

Semantics

Type Source Name
disease MESH Immunocompromised Patients
disease MESH COVID-19
pathway REACTOME Immune System
disease MESH infections
disease IDO history
disease MESH herpes zoster
disease MESH influenza
disease MESH Infectious Diseases
disease IDO infection
disease MESH vaccine preventable diseases
disease MESH pneumococcal infections
disease MESH measles
pathway KEGG Measles
disease MESH autoimmune diseases
disease MESH hematological malignancies
drug DRUGBANK Coenzyme M
disease IDO immunosuppression
drug DRUGBANK Indoleacetic acid
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH complications
drug DRUGBANK Azathioprine
disease MESH chickenpox
disease MESH mumps
disease MESH rubella
disease MESH immune diseases
disease MESH vasculitis
disease MESH systemic sclerosis
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH amyloidosis
disease MESH IgG4 related disease
disease IDO cell
disease MESH malignancy
pathway KEGG Primary immunodeficiency
disease IDO primary immunodeficiency
disease IDO immunodeficiency
disease MESH agammaglobulinemia
disease MESH hematological diseases
disease IDO susceptibility
disease IDO process
disease MESH privacy
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH common variable immunodeficiency
disease IDO blood
disease MESH Hepatitis
disease IDO immunocompetence
disease MESH Chronic Diseases
drug DRUGBANK Trestolone
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Colitis
drug DRUGBANK Guanosine
drug DRUGBANK Efavirenz
disease MESH Rheumatic Diseases

Original Article

(Visited 1 times, 1 visits today)